Epilepsy News

Clinical outcome assessments currently used for people with Lennox-Gastaut syndrome and Dravet syndrome were “not fit” for evaluating non-seizure outcomes, researchers said, prompting the development of a global clinical impression measure.

NeuroPace Inc. announced that the first patient with Lennox-Gastaut Syndrome was treated in its investigational device exemption feasibility study, which will evaluate the company’s neuromodulation technology.

Kriya Therapeutics Inc. announced the acquisition of biotech company Redpin Therapeutics Inc., bolstering Kriya’s neurology therapeutic portfolio by adding gene therapy programs for epilepsy and trigeminal neuralgia.

In this edition, we bring you more news and Healio-exclusive interviews from the American Neurological Association Annual Meeting.

CHICAGO – For persons with epilepsy, cognitive impairment was reduced for those with the generalized form of the disease, as well as for those who are prescribed more than one type of therapy, according to a poster at ANA 2022.

In this edition, COVID-19 patients at risk for post-infection complications; VR for patients with back pain; FDA requests further analysis of Supernus Parkinson’s treatment and more.

The FDA has granted breakthrough device designation to neurotechnology company Axoft for its brain-machine interface to treat long-term neurological disorders.

Patients with hypertension who received angiotensin receptor blocking therapy had a significant decrease in incidence of epilepsy, researchers reported in JAMA Neurology.

LAS VEGAS — Cannabinoids have been shown to effectively control seizures across the epilepsy spectrum; however, quality control of products remains a challenge, according to a presenter at BRAINWeek 2022.

Neurological disorders like epilepsy can have significant, life-altering implications for patients, their families and caregivers.